Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Importance of continuous treatment with intravitreal aflibercept injections in patients with neovascular age-related macular degeneration-12-month post hoc analysis of the PERSEUS real-world evidence study.
Wachtlin J, Eter N, Hasanbasic Z, Keramas G, Rech C, Sachs H, Schilling H, Wiedemann P, Framme C. Wachtlin J, et al. Among authors: hasanbasic z. Graefes Arch Clin Exp Ophthalmol. 2021 Mar;259(3):601-611. doi: 10.1007/s00417-020-04803-8. Epub 2020 Aug 13. Graefes Arch Clin Exp Ophthalmol. 2021. PMID: 32789651 Free PMC article.
Aflibercept for Patients with Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in Germany: Twelve-Month Outcomes of PERSEUS.
Framme C, Eter N, Hamacher T, Hasanbasic Z, Jochmann C, Johnson KT, Kahl M, Sachs H, Schilling H, Thelen U, Wiedemann P, Wachtlin J; Prospective Noninterventional Study to Assess the Effectiveness of Aflibercept in Routine Clinical Practice in Patients with Neovascular Age-Related Macular Degeneration Study Group. Framme C, et al. Among authors: hasanbasic z. Ophthalmol Retina. 2018 Jun;2(6):539-549. doi: 10.1016/j.oret.2017.09.017. Epub 2017 Nov 20. Ophthalmol Retina. 2018. PMID: 31047606
PERSEUS 24-month analysis: a prospective non-interventional study to assess the effectiveness of intravitreal aflibercept in routine clinical practice in Germany in patients with neovascular age-related macular degeneration.
Eter N, Hasanbasic Z, Keramas G, Rech C, Sachs H, Schilling H, Wachtlin J, Wiedemann P, Framme C; PERSEUS Study Group. Eter N, et al. Among authors: hasanbasic z. Graefes Arch Clin Exp Ophthalmol. 2021 Aug;259(8):2213-2223. doi: 10.1007/s00417-021-05073-8. Epub 2021 Feb 6. Graefes Arch Clin Exp Ophthalmol. 2021. PMID: 33547967 Free PMC article.
Treatment of age-related neovascular macular degeneration: the patient's perspective.
Müller S, Ehlken C, Bauer-Steinhusen U, Lechtenfeld W, Hasanbasic Z, Agostini H, Wilke T. Müller S, et al. Among authors: hasanbasic z. Graefes Arch Clin Exp Ophthalmol. 2017 Nov;255(11):2237-2246. doi: 10.1007/s00417-017-3739-1. Epub 2017 Aug 4. Graefes Arch Clin Exp Ophthalmol. 2017. PMID: 28776095 Free PMC article.
[Retrospective investigation of anti-VEGF treatment reality and effectiveness in patients with neovascular age-related macular degeneration (AMD) in Germany: treatment reality of ranibizumab for neovascular AMD in Germany].
Ziemssen F, Eter N, Fauser S, Bopp S, Radermacher M, Hasanbasic Z, Holz FG; AURA-Studiengruppe. Ziemssen F, et al. Among authors: hasanbasic z. Ophthalmologe. 2015 Mar;112(3):246-54. doi: 10.1007/s00347-014-3217-7. Ophthalmologe. 2015. PMID: 25668709 German.
Sustained disease control with aflibercept 8 mg: a new benchmark in the management of retinal neovascular diseases.
Korobelnik JF, Lanzetta P, Wykoff CC, Wong TY, Zhang X, Morgan-Warren P, Fitzpatrick S, Leal S, Brunck L, Hasanbasic Z, Chu KW, Reed K, Sivaprasad S. Korobelnik JF, et al. Among authors: hasanbasic z. Eye (Lond). 2024 Dec;38(17):3218-3221. doi: 10.1038/s41433-024-03312-w. Epub 2024 Aug 31. Eye (Lond). 2024. PMID: 39217260 Free PMC article. No abstract available.